Driven by skyrocketing demand for GLP-1 receptor agonists and peptide-drug conjugates (PDCs), the global peptide therapeutics market is projected to surge to $332.95 billion by 2034. However, traditional TIDES manufacturing is bottlenecked by development uncertainty, process inefficiencies, and massive waste generation.

In this webinar, we explore how to scale up TIDES production by integrating hybrid synthesis, enzymatic ligation, and continuous flow for multi-ton production. Experts from GlobalData and Asymchem, a leader in pharmaceutical manufacturing industry, will discuss advanced strategies to overcome traditional limitations. Additionally, the panel will reveal how continuous-flow electrochemical technology redefines disulfide bond formation for oral cyclic peptides, cutting waste by over 90% while boosting throughput up to 20-fold.

Finally, attendees will gain insights into achieving end-to-end solutions, from enzyme engineering through to commercial production, exploring how these technologies can optimise your existing operations. The session will break down the practical steps required to deploy automated, high-throughput biocatalysis and continuous-flow chemistry to help you scale for global clients.

Key learnings:

• Market drivers and manufacturing challenges facing the global peptide drug market
• How AI-driven enzymatic platforms overcome traditional chemical synthesis limitations
• Technical workflows of continuous-flow electrochemistry for high-throughput cyclic peptide manufacturing
• Strategies for implementing hybrid synthesis to achieve efficient, multi-ton commercial production